Naperville, IL -- (SBWIRE) -- 03/10/2014 -- Reportstack, provider of premium market research reports announces the addition of Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis market report to its offering
The report entitled „Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis“ is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.
The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from La Merie‘ proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. A structured analysis was performed for the ADC pipeline, for stakeholders of the ADC industry, for state-of-the art and emerging ADC technologies, for the ADC manufacturing and service industry, and business activities. The report identifies trends for those ADC technologies (target, antibody, drug, linker and conjugation systems) which are of interest for the industry.
The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years.
Spefically, the ADC pipeline analysis describes preclinical, non-clinical and clinical ADC projects and R&D programs. It evaluates the ADC targets in relation to drug and linker systems, and also investigates the clinical success and reasons for failures of antibody-drug conjugates.
The stakeholder analysis compares companies with their peers in the respective group of development, technology and manufacturing companies and further categorizes them within the respective group to find out their competitive situation.
The analysis pays special attention to the importance of target selection, to emerging trends of new targeting moieties beyond full-length, canonical antibodies, to the expansion of the use of ADCs in non-cancer indications, to the opportunities arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs.
Crticial issues of ADCs, such as therapeutic window, druggable targets, manufacturing and financing are addressed and opportunities outlined.
Who will benefit from the report:
Investors
Business developers
Licensing managers
Technology officers
R&D Management
Business & Competitive Intelligence Analysts
Scientific Analysts
R&D Planning
Portfolio Managers
What will you find in the report?
Company profiles of ADC stakeholders
ADC drug profiles
ADC business agreements
ADC pipeline description and analysis
Clinical attrition rate of ADCs and reasons for failure
ADC target description and analysis
Current and future drugs, linkers and conjugation systems
Industry preferences for drugs and linkers
Alternative targeting moieties
New uses of ADCs and immunoconjugates
CMOs for manufacturing of ADCs
Competitors in development, technology or manufacturing
Commercial value of ADC products and technologies
Companies mentioned in the report
Abbott Contract Manufacturing
AbbVie
AbGenomics
Ablynx
ACES Pharma
ADC Therapeutics
Adcanced Proteome Therapeutics
Aeterna Zentaris
Affinicon
Albany Molecular Research Inc (AMRI)
Allozyne
Ambrx
Amgen
Amunix
Arrowhead Research
Astellas Pharma
AstraZeneca
Auven Therapeutics
Baxter BioPharma Solutions
Bayer HealthCare Pharmaceuticals
BIND Therapeutics
Biotecnol
Biotest
Bristol-Myers Squibb
BSP Pharmaceuticals
Carbogen Amcis
Catalent Biologics
Celgene
Celldex Therapeutics
Centrose
Coldstream Laboratories
Concortis Biosystems
CytomX
Daiichi Sankyo
Eli Lilly
Endo Pharmaceuticals
Esperance Pharmaceuticals
Evonik Industries
f-star
Fujifilm Diosynth Biotechnologies
Genmab
GlaxoSmithKline
Glykos
Goodwin Biotechnology
Wilex (Heidelberg Pharma)
Helix Biopharma
Heraeus
Igenica
Immune Pharmaceuticals
ImmunoGen
Immunomedics
Innate Pharma
Intellect Neurosciences
Janssen Research & Development
Lonza
Macrogenics
Meditope Biosciences
Menarini
Merck
Mersana Therapeutics
Molecular Partners
Nerviano Medical Sciences
Novartis
Novasep
Oncomatrix
Oxford BioTherapeutics
Pfizer
Philogen
Photobiotics
Phylogica
Pierre Fabre Group
Pierre Fabre Medicament Production
Piramal
Polytherics
Progenics Pharmaceuticals
Quanta Biodesign
Redwood Biodesign
Roche
Sanofi
Seattle Genetics
Serina Therapeutics
Shire
Sigma Aldrich SAFC
Sorrento Therapeutics
Spirogen
Stem CentRx
Sutro Biopharma
SynAffix
Synthon Biopharmaceuticals
Takeda Pharmaceutical
The Chemistry Research Solution
TUBE Pharma
University of California San Diego
WuXi PharmaTech
Zhejiang Medicine
Zymeworks
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/151312/antibody-drug-conjugates-2014-a-business-technology-pipeline-analysis.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###